My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 2643

    1.

    A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

    Breast Cancer Res. 2008;10(5):R88. Epub 2008 Oct 17.PMID: 18928543 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

    Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

    Breast Cancer Res Treat. 2009 Jan;113(2):275-83. Epub 2008 Mar 4.PMID: 18311582 [PubMed - indexed for MEDLINE]Related articles

    3.

    Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.

    Bièche I, Girault I, Urbain E, Tozlu S, Lidereau R.

    Breast Cancer Res. 2004;6(3):R252-63. Epub 2004 Mar 26.PMID: 15084249 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.

    Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA.

    J Mol Endocrinol. 2009 Feb;42(2):87-103. Epub 2008 Nov 4. Erratum in: J Mol Endocrinol. 2009 Apr;42(4):357. PMID: 18984771 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.

    Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY.

    BMC Cancer. 2006 Apr 12;6:92.PMID: 16608533 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.

    Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM.

    Breast Cancer Res Treat. 2009 Jan;113(2):253-60. Epub 2008 Feb 26.PMID: 18299979 [PubMed - indexed for MEDLINE]Related articles

    7.

    A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

    Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

    Clin Cancer Res. 2008 Mar 15;14(6):1744-52.PMID: 18347175 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.

    Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, Lazar V, Spyratos F, Tubiana-Hulin M, Cohen P, Dessen P, Lidereau R, Bièche I.

    J Mol Endocrinol. 2007 Oct;39(4):305-18.PMID: 17909269 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

    Newby JC, Johnston SR, Smith IE, Dowsett M.

    Clin Cancer Res. 1997 Sep;3(9):1643-51.PMID: 9815855 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

    Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.PMID: 18925950 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.

    van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA.

    J Natl Cancer Inst. 2000 Jan 19;92(2):120-7.PMID: 10639513 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

    Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.

    Breast Cancer Res. 2008;10(5):R81. Epub 2008 Sep 29.PMID: 18823530 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.

    Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, Langer R, Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Hoefler H.

    Breast Cancer Res Treat. 2009 Nov;118(1):45-56. Epub 2008 Oct 17.PMID: 18925433 [PubMed - indexed for MEDLINE]Related articles

    14.

    Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.

    Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I.

    Clin Cancer Res. 2003 Apr;9(4):1259-66.PMID: 12684393 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Overview of resistance to systemic therapy in patients with breast cancer.

    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

    Adv Exp Med Biol. 2007;608:1-22. Review.PMID: 17993229 [PubMed - indexed for MEDLINE]Related articles

    16.

    Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.

    Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM.

    Breast Cancer Res. 2008;10(5):R89. Epub 2008 Oct 23.PMID: 18947395 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

    Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N.

    J Natl Cancer Inst. 2004 Apr 7;96(7):516-23.PMID: 15069113 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

    J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.PMID: 16145046 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.

    Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.

    Clin Cancer Res. 2004 Nov 15;10(22):7490-9.PMID: 15569979 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

    Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.

    Breast Cancer Res Treat. 2010 Jan;119(2):283-93. Epub 2009 Feb 24.PMID: 19238537 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk